last updated: 2 months ago

last updated: 2 months ago

Remepy logo

Remepy

Remepy

Remepy

Pioneering hybrid drugs

Pioneering hybrid drugs

Pioneering hybrid drugs

Biotechnology Research

Biotechnology Research

⋅

⋅

New York

New York

US

US

⋅

⋅

51–200 employees

51–200 employees

⋅

⋅

Founded:

Founded:

January 2022

January 2022

Overview

Overview

Remepy is Pioneering Hybrid Drugs™.

Many medical conditions are better treated by combining pharmaceutical and non-pharmaceutical treatments. Hybrid drugs are a new type of drug asset, that combines traditional drugs with proprietary treatment protocols delivered measured and adapted using our AI capabilities.

Remepy’s Digital Molecules™ are designed to be the software apps within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug and are constantly measured and tracked and personalized using advanced AI capabilities.

The Digital Molecules™ enhance brain functions that balance the patient's neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance. We also address physical, motor, psychological, and behavioral symptoms

Remepy partners with pharma companies to bring Hybrid Drugs™ to market that will combine Remepy’s Digital Molecule™ and traditional drug components.

Remepy is Pioneering Hybrid Drugs™.

Many medical conditions are better treated by combining pharmaceutical and non-pharmaceutical treatments. Hybrid drugs are a new type of drug asset, that combines traditional drugs with proprietary treatment protocols delivered measured and adapted using our AI capabilities.

Remepy’s Digital Molecules™ are designed to be the software apps within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug and are constantly measured and tracked and personalized using advanced AI capabilities.

The Digital Molecules™ enhance brain functions that balance the patient's neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance. We also address physical, motor, psychological, and behavioral symptoms

Remepy partners with pharma companies to bring Hybrid Drugs™ to market that will combine Remepy’s Digital Molecule™ and traditional drug components.

Founder

Founder

Remepy logo

Or Shoval

Or Shoval

Co-Founder & Co-CEO at Remepy

Co-Founder & Co-CEO at Remepy

Employee Growth

Employee Growth

TOTAL EMPLOYEES

TOTAL EMPLOYEES

89

89

6m GROWTH

6m GROWTH

22%

22%

1y GROWTH

1y GROWTH

46%

46%

OCT'25NOV'25DEC'25JAN'26FEB'26MAR'26APR'26MAY'26JUN'26JUL'26AUG'26SEP'26

Department Distribution

Department Distribution

TOTAL EMPLOYEES

TOTAL EMPLOYEES

89

89

Engineering

Engineering

Program and Project Management

Program and Project Management

Arts and Design

Arts and Design

Entrepreneurship

Entrepreneurship

Business Development

Business Development

Department Growth

Department Growth

6m GROWTH

6m GROWTH

1y GROWTH

1y GROWTH

Engineering

20%

33%

Program and Project Management

80%

200%

Arts and Design

33%

167%

Entrepreneurship

14%

14%

Business Development

0%

-12%

Web Engagement

pages per visit

pages per visit

2.5

2.5

monthly visits

monthly visits

6,207

6,207

JUN'26JUL'26AUG'26

Web Traffic by Country

Web Traffic by Country

Israel

68.7%

Israel

68.7%

United States

31.3%

United States

31.3%

Web Traffic Sources

Web Traffic Sources

Direct

30.3%

Direct

30.3%

Search

37.8%

Search

37.8%

Social

6.8%

Social

6.8%

Referrals

9.5%

Referrals

9.5%

AI

2.3%

AI

2.3%

funding round

2

total funding raised

$62M

last round type

Series A

last round amount

$36M

announced on

$36M

funding round

2

total funding raised

$62M

last round type

Series A

last round amount

$36M

announced on

$36M

lead investors

lead investors

O.G. Venture Partners, M Ventures, NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital, IT-Farm Corp

O.G. Venture Partners, M Ventures, NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital, IT-Farm Corp